BeiGene
BGNE
#963
Rank
ยฃ15.93 B
Marketcap
ยฃ140.42
Share price
1.02%
Change (1 day)
0.58%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Total debt

Total debt on the balance sheet as of September 2024 : ยฃ0.87 Billion

According to BeiGene 's latest financial reports the company's total debt is ยฃ0.87 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

BeiGene - Total debt on balance sheet (from 2014 to 2024)

Total debt by year

Year Total debt Change
2023-12-31ยฃ0.73 B48.04%
2022-12-31ยฃ0.49 B-4.16%
2021-12-31ยฃ0.51 B24.82%
2020-12-31ยฃ0.41 B94.93%
2019-12-31ยฃ0.21 B35.32%
2018-12-31ยฃ0.15 B28.25%
2017-12-31ยฃ0.12 B770.07%
2016-12-31ยฃ14 M-0.13%
2015-12-31ยฃ14.02 M57.81%
2014-12-31ยฃ8.88 M-46.42%
2013-12-31ยฃ16.58 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ0.40 B-53.49%๐Ÿ‡บ๐Ÿ‡ธ USA